Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Catalyst Pharmaceuticals Inc

Healthcare US CPRX

31.39USD
0.01(0.03%)

Last update at 2026-06-23T18:32:00Z

Day Range

31.3731.40
LowHigh

52 Week Range

19.0526.58
LowHigh

Fundamentals

  • Previous Close 31.38
  • Market Cap3151.47M
  • Volume551353
  • P/E Ratio15.54
  • Dividend Yield-%
  • EBITDA295.65M
  • Revenue TTM588.99M
  • Revenue Per Share TTM4.82
  • Gross Profit TTM 489.03M
  • Diluted EPS TTM1.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 283.51M 216.26M 94.51M 104.72M 52.67M
Minority interest - - - - -
Net income 214.33M 163.89M 71.41M 83.08M 39.48M
Selling general administrative 193.75M 167.74M 47.02M 28.71M 23.48M
Selling and marketing expenses - 10.00M 86.69M 29.47M 26.15M
Gross profit 501.74M 422.89M 346.24M 179.81M 118.95M
Reconciled depreciation 37.87M 37.77M 24.35M 1.24M 0.19M
Ebit 283.51M 195.12M 86.81M 100.60M 52.19M
Ebitda 321.01M 232.90M 119.69M 101.84M 52.38M
Depreciation and amortization 37.50M 37.77M 32.88M 1.24M 0.19M
Non operating income net other - - - 2.88M 0.28M
Operating income 257.78M 195.12M 86.81M 101.84M 52.38M
Other operating expenses 331.21M 296.61M 311.39M 112.36M 88.45M
Interest expense - - - -4.12000M 0.47M
Tax provision 69.19M 52.37M 18.77M 21.64M 13.19M
Interest income - - - - -
Net interest income 24.77M 16.06M 4.67M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 69.19M 52.37M 23.10M 21.64M 13.19M
Total revenue 588.99M 491.73M 398.20M 214.20M 140.83M
Total operating expenses 243.96M 227.76M 259.43M 77.97M 66.56M
Cost of revenue 87.25M 68.84M 51.97M 34.39M 21.88M
Total other income expense net 25.74M 21.14M 7.70M 2.88M 0.28M
Discontinued operations - - - - -
Net income from continuing ops 214.33M 163.89M 62.04M 83.08M 39.48M
Net income applicable to common shares - - - 83.08M 39.48M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1106.81M 851.41M 471.91M 375.63M 237.79M
Intangible assets 131.67M 156.67M 194.05M 32.47M -
Earning assets - - - - -
Other current assets 19.43M 21.03M 12.54M 5.16M 4.35M
Total liab 152.54M 123.78M 84.03M 75.21M 30.96M
Total stockholder equity 954.27M 727.63M 387.88M 300.42M 206.83M
Deferred long term liab - - - - -
Other current liab 135.51M 102.79M 60.17M 53.28M 0.24M
Common stock 0.12M 0.12M 0.11M 0.10M 0.10M
Capital stock 0.12M 0.12M 0.11M 0.10M 0.10M
Retained earnings 474.19M 285.16M 121.27M 49.86M -26.31000M
Other liab - - - 14.06M -
Good will - - - - -
Other assets - - 0.00000M 18.75M 23.71M
Cash 709.17M 517.55M 137.64M 298.39M 171.44M
Cash and equivalents - - - - -
Total current liabilities 147.15M 120.68M 76.06M 57.59M 27.06M
Current deferred revenue - - 0.73M - 23.74M
Net debt -706.38400M -514.36500M -134.07900M -294.50100M -167.55100M
Short term debt 0.44M 0.40M 0.37M 0.34M 0.31M
Short long term debt - - - - -
Short long term debt total 2.79M 3.19M 3.56M 3.89M 3.89M
Other stockholder equity 479.96M 442.29M 266.49M 250.43M 233.19M
Property plant equipment - - - 0.85M 3.98M
Total current assets 894.03M 623.61M 219.33M 320.80M 210.11M
Long term investments 22.54M 21.56M 16.49M - -
Net tangible assets - - - 267.95M 206.83M
Short term investments - - - 0.00000M 19.82M
Net receivables 128.27M 65.49M 53.51M 10.44M 6.62M
Long term debt - - - - -
Inventory 37.17M 19.54M 15.64M 6.80M 7.87M
Accounts payable 11.20M 16.59M 14.79M 3.98M 2.77M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.06M 0.01M 0.02M -0.14800M
Additional paid in capital - - - - -
Common stock total equity - - - 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 49.86M -26.31000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -0.00000M 0.00900M 0.00900M
Deferred long term asset charges - - - - -
Non current assets total 212.78M 227.80M 252.58M 54.83M 27.68M
Capital lease obligations 2.79M 3.19M 3.56M 3.89M 3.89M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M -0.55600M -255.18400M 19.24M -10.00000M
Change to liabilities - - - 17.60M 4.03M
Total cashflows from investing activities -0.05800M -0.55600M - 9.21M -11.02100M
Net borrowings - - - - -
Total cash from financing activities -16.99400M 140.66M -10.85700M 1.69M -8.14300M
Change to operating activities - - - 15.28M 10.36M
Net income 214.33M 163.89M 71.41M 83.08M 39.48M
Change in cash 191.62M 379.92M -160.75900M 126.95M 41.21M
Begin period cash flow 517.55M 137.64M 298.39M 171.44M 130.24M
End period cash flow 709.17M 517.55M 137.64M 298.39M 171.44M
Total cash from operating activities 208.67M 239.81M 143.60M 116.05M 60.37M
Issuance of capital stock 0.00000M 141.00M - - -
Depreciation 37.87M 37.77M 33.14M 1.24M 0.19M
Other cashflows from investing activities - 13.14M - -10.00000M -
Dividends paid - - - - -
Change to inventory -18.08900M -3.89700M -4.73900M 1.06M -3.21900M
Change to account receivables -61.00100M -11.96200M -43.07500M -3.82000M -0.63200M
Sale purchase of stock -25.30000M -0.29600M -0.98200M -6.90700M -12.08900M
Other cashflows from financing activities -6.36300M -0.03900M -13.64900M 4.50M -0.15300M
Change to netincome - - - 12.84M 15.39M
Capital expenditures 0.06M 0.56M 198.52M 0.03M 1.02M
Change receivables - - - -3.82000M -0.63200M
Cash flows other operating - - - 4.04M 5.13M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 126.95M 41.21M
Change in working capital -60.89500M 30.91M -37.32400M 13.73M 5.02M
Stock based compensation 24.78M 22.25M 14.25M 7.91M 6.07M
Other non cash items -0.56300M -5.63200M 79.94M 5.16M 0.29M
Free cash flow 208.61M 239.25M -54.92400M 116.02M 59.35M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CPRX
Catalyst Pharmaceuticals Inc		 0.01 0.03% 31.39 15.54 10.73 5.35 3.34 4.21 8.38
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.28 0.86% 617.77 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Catalyst Pharmaceuticals Inc

355 Alhambra Circle, Coral Gables, FL, United States, 33134

Key Executives

Name Title Year Born
Mr. Patrick J. McEnany Co-Founder, Chairman, Pres & CEO 1947
Ms. Alicia Grande C.M.A., CPA, CMA, CPA Chief Accounting Officer, VP, Treasurer & CFO 1971
Dr. Steven R. Miller Ph.D. COO & Chief Scientific Officer 1962
Dr. Gary Ingenito M.D., Ph.D. Chief Medical & Regulatory Officer 1956
Dr. Preethi Sundaram Ph.D. Chief Strategy Officer 1976
Ms. Mary Coleman VP & Head of Investor Relations NA
Mr. Brian Elsbernd J.D. Chief Compliance Officer & Chief Legal Officer 1964
Mr. Pete Curry Sr. VP of Sales NA
Mr. Jeffrey Del Carmen Chief Commercial Officer 1971
Mr. Philip B. Schwartz Corp. Sec. 1955

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.